千金药业
(600479)
| 流通市值：43.48亿 | | | 总市值：44.05亿 |
| 流通股本：4.19亿 | | | 总股本：4.24亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,005,023,395.38 | 3,629,804,492.14 | 2,714,645,993.63 | 1,924,281,007.44 |
| 营业收入 | 1,005,023,395.38 | 3,629,804,492.14 | 2,714,645,993.63 | 1,924,281,007.44 |
| 二、营业总成本 | 922,900,905.5 | 3,317,463,364.57 | 2,475,132,343.8 | 1,744,641,940.28 |
| 营业成本 | 530,331,604.73 | 1,946,338,663.18 | 1,464,599,086.37 | 1,055,148,991.3 |
| 税金及附加 | 10,793,751.45 | 38,288,394.09 | 28,518,550.15 | 19,315,782.14 |
| 销售费用 | 254,595,958.22 | 849,485,024.18 | 656,039,950.54 | 438,686,688.89 |
| 管理费用 | 65,375,218.16 | 290,207,399.17 | 195,171,032.54 | 123,360,245.32 |
| 研发费用 | 61,461,708.51 | 220,204,530.81 | 144,395,569.53 | 114,750,778.24 |
| 财务费用 | 342,664.43 | -27,060,646.86 | -13,591,845.33 | -6,620,545.61 |
| 其中:利息费用 | 21,000 | 1,114,983.71 | 1,645,932.42 | 1,389,377.97 |
| 其中:利息收入 | 1,744,875.55 | 35,532,015.16 | 18,890,712.67 | 10,290,307 |
| 加:公允价值变动收益 | 1,059,631.13 | 634,598.12 | -1,009,742.23 | 2,883,219.09 |
| 加:投资收益 | 6,059,608.71 | 15,582,312.28 | 2,419,826.5 | -2,924,835.31 |
| 资产处置收益 | - | 497,372.67 | - | - |
| 资产减值损失(新) | 88,844.47 | -7,823,288.98 | -1,996,475.41 | 833,771.59 |
| 信用减值损失(新) | -11,951,166.47 | -4,848,760.54 | -10,262,645.86 | -15,281,274.91 |
| 其他收益 | 2,659,204.94 | 15,727,291.07 | 11,925,242.84 | 8,739,683.79 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 80,038,612.66 | 332,110,652.19 | 240,589,855.67 | 173,889,631.41 |
| 加:营业外收入 | 37,752.55 | 5,359,437.62 | 2,132,361.67 | 804,821.54 |
| 减:营业外支出 | 605,377.84 | 2,162,515.78 | 1,153,783.95 | 949,164.02 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 79,470,987.37 | 335,307,574.03 | 241,568,433.39 | 173,745,288.93 |
| 减:所得税费用 | 7,151,983.21 | 32,698,873.02 | 28,203,388.52 | 24,677,298.61 |
| 六、净利润 | 72,319,004.16 | 302,608,701.01 | 213,365,044.87 | 149,067,990.32 |
| 持续经营净利润 | 72,319,004.16 | 302,608,701.01 | 213,365,044.87 | 149,067,990.32 |
| 归属于母公司股东的净利润 | 53,155,316.53 | 230,756,619.25 | 168,076,563.28 | 117,723,047.32 |
| 少数股东损益 | 19,163,687.63 | 71,852,081.76 | 45,288,481.59 | 31,344,943 |
| (一)基本每股收益 | 0.13 | 0.56 | 0.4 | 0.28 |
| (二)稀释每股收益 | 0.13 | 0.56 | 0.4 | 0.28 |
| 八、其他综合收益 | - | -13,947.49 | -75,373.07 | -246.99 |
| 归属于母公司股东的其他综合收益 | - | -13,947.49 | -75,373.07 | -246.99 |
| 九、综合收益总额 | 72,319,004.16 | 302,594,753.52 | 213,289,671.8 | 149,067,743.33 |
| 归属于母公司股东的综合收益总额 | 53,155,316.53 | 230,742,671.76 | 168,001,190.21 | 117,722,800.33 |
| 归属于少数股东的综合收益总额 | 19,163,687.63 | 71,852,081.76 | 45,288,481.59 | 31,344,943 |
| 公告日期 | 2025-04-29 | 2025-04-29 | 2024-10-30 | 2024-08-28 |
| 审计意见(境内) | | 标准无保留意见 | | |